A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

Overview

Journal Dermatol Ther (Heidelb)

Date 2012 Dec 4

PMID 23205325

Citations 1

Authors

Bruce E Strober

Jennifer Clay Cather

David Cohen

Jeffrey J Crowley

Kenneth B Gordon

Alice B Gottlieb

Arthur F Kavanaugh

Neil J Korman

Gerald G Krueger

Craig L Leonardi

Sergio Schwartzman

Jeffrey M Sobell

Gary E Solomon

Melodie Young

Affiliations

Soon will be listed here.

Abstract

Introduction: Clinicians may be confronted with difficult-to-treat psoriasis cases for which there are scant data to rely upon for guidance. To assist in managing such patients, who are typically excluded from clinical trials, a consensus panel of 14 experts in the field of psoriasis was formed to conduct a Delphi method exercise.

Methods: The exercise consisted of both survey questionnaires and a live meeting to review and discuss current data (as of 2009, when the exercise was conducted) and arrive at a consensus for optimal treatment options. Seventy difficult treatment scenarios were identified, and the top 24 were selected for discussion at the live meeting.

Results: Five of the 24 discussed case scenarios are presented in this article: (1) moderate-to-severe psoriasis that has failed to respond to all currently approved therapies for psoriasis; (2) palmoplantar psoriasis that is unresponsive to topical therapy and phototherapy; (3) erythrodermic psoriasis; (4) pustular psoriasis; and (5) the preferred therapeutic choice to combine with low-dose methotrexate. A previous article (part 1) presented six other scenarios.

Conclusion: The Delphi exercise resulted in guidelines for practicing physicians to utilize when confronted with patients with challenging cases of psoriasis.

Citing Articles

Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations.

Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu C J Neurol. 2013; 261(9):1662-76.

PMID: 24366648 PMC: 4155170. DOI: 10.1007/s00415-013-7209-3.

References

Gladman D, Mease P, Ritchlin C, Choy E, Sharp J, Ory P . Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007; 56(2):476-88. DOI: 10.1002/art.22379. View

Wolska H, Jablonska S, BOUNAMEAUX Y . Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis. J Am Acad Dermatol. 1983; 9(6):883-9. DOI: 10.1016/s0190-9622(83)70203-3. View

Kragballe K, Austad J, Barnes L, Bibby A, De La Brassinne M, Cambazard F . A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006; 154(6):1155-60. DOI: 10.1111/j.1365-2133.2006.07236.x. View

Solomon D, Avorn J, Katz J, Weinblatt M, Setoguchi S, Levin R . Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54(12):3790-8. DOI: 10.1002/art.22255. View

Zangrilli A, Papoutsaki M, Talamonti M, Chimenti S . Long-term efficacy of adalimumab in generalized pustular psoriasis. J Dermatolog Treat. 2008; 19(3):185-7. DOI: 10.1080/09546630701759587. View

Kokelj F, Plozzer C, Torsello P, Trevisan G . Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol. 1998; 11(2):177-9. View

Rym B, Mourad M, Bechir Z, Dalenda E, Faika C, Iadh A . Erythroderma in adults: a report of 80 cases. Int J Dermatol. 2005; 44(9):731-5. DOI: 10.1111/j.1365-4632.2004.02100.x. View

Ahdout J, Mandel H, Chiu M . Erythroderma in a patient taking acitretin for plaque psoriasis. J Drugs Dermatol. 2008; 7(4):391-4. View

Weinberg J . Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003; 72(5):396-8. View

10.

Korstanje M, van Breda Vriesman C, VAN DE STAAK W . Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol. 1990; 23(2 Pt 1):320-1. DOI: 10.1016/s0190-9622(08)81244-3. View

11.

Yawalkar N, Hunger R . Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology. 2008; 218(1):79-83. DOI: 10.1159/000167802. View

12.

Xiao T, Li B, He C, Chen H . Juvenile generalized pustular psoriasis. J Dermatol. 2007; 34(8):573-6. DOI: 10.1111/j.1346-8138.2007.00334.x. View

13.

Ozawa A, Ohkido M, Haruki Y, Kobayashi H, Ohkawara A, Ohno Y . Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol. 1999; 26(3):141-9. DOI: 10.1111/j.1346-8138.1999.tb03444.x. View

14.

Pettey A, Balkrishnan R, Rapp S, Fleischer A, Feldman S . Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003; 49(2):271-5. DOI: 10.1067/s0190-9622(03)01479-8. View

15.

Spuls P, Rozenblit M, Lebwohl M . Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatolog Treat. 2003; 14 Suppl 2:17-20. DOI: 10.1080/jdt.14.s2.17.20. View

16.

Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J . Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008; 7(10):940-6. View

17.

Sigurdsson V, Toonstra J, van Vloten W . Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol. 1996; 35(1):53-7. DOI: 10.1016/s0190-9622(96)90496-x. View

18.

Varma R, Cafardi J, Cantrell W, Elmets C . Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study. Am J Clin Dermatol. 2008; 9(2):105-9. DOI: 10.2165/00128071-200809020-00003. View

19.

SPATZ S, Rudnicka A, McDonald C . Mycophenolic acid in psoriasis. Br J Dermatol. 1978; 98(4):429-35. DOI: 10.1111/j.1365-2133.1978.tb06537.x. View

20.

Stern R, Nichols K, Vakeva L . Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med. 1997; 336(15):1041-5. DOI: 10.1056/NEJM199704103361501. View